Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 323-330

  Katsuno, Kenji ^a   Fujimori, Yoshikazu ^a   Takemura, Yukiko ^a   Hiratochi, Masahiro ^a   Itoh, Fumiaki ^a   Komatsu, Yoshimitsu ^a   Fujikura, Hideki ^a   Isaji, Masayuki ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGLYCONE; ANTIDIABETIC AGENT; CARBOXYMETHYLCELLULOSE; GLUCOSE; PHLORETIN; PHLORIZIN; SERGLIFLOZIN; SERGLIFLOZIN A; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; CHO CELL; CONTROLLED STUDY; DIABETES MELLITUS; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROLYTE BALANCE; FEMALE; GENE AMPLIFICATION; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; GLUCOSURIA; HYPERGLYCEMIA; INHIBITION KINETICS; INSULIN RELEASE; KIDNEY TUBULE ABSORPTION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RAT;

ABSORPTION; ANIMALS; BLOOD GLUCOSE; DOGS; ELECTROLYTES; ERYTHROCYTES; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; GLUCOSIDES; GLYCOSURIA; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 33845873376     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.110296     Document Type: Article

References (35)

1. Bishop JH, Green R, and Thomas S (1979) Free-flow reabsorption of glucose, sodium, osmoles and water in rat proximal convoluted tubule. J Physiol (Lond) 288:331-351.
2. Baron AD (1998) Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Diabetes Res Clin Pract 40 (Suppl):S51-S55.
3. Calado J, Soto K, Clemente C, Correia P, and Rueff J (2004) Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum Genet 114:314-316.
4. DeFronzo RA (1999) Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303.
5. Ehrenkranz JR, Lewis NG, Kahn CR, and Roth J (2005) Phlorizin: a review. Diabetes Metab Res Rev 21:31-38.
6. Ferre P (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (Suppl):S43-S50.
7. Ichikawa K, Yamato T, Ojima K, Tsuji A, Ishikawa K, Kusama H, and Kojima M (2002) Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol 29:423-427.
8. Ikenoue T, Okazaki K, Fujitani S, Tsuchiya Y, Akiyoshi M, Maki T, and Kondo N (1997) Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4- isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull 20:354-359.
9. +/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Investig 93:397-404.
10. Kees KL, Fitzgerald JJ Jr, Steiner KE, Mattes JF, Mihan B, Tosi T, Mondoro D, and McCaleb ML (1996) New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl) (trifluoromethyl) pyrazoles and -pyrazolones. J Med Chem 27:3920-3928.
11. Leverve XM, Guigas B, Detaille D, Batandier C, Koceir EA, Chauvin C, Fontaine E, and Wiernsperger NF (2003) Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29:6S88-94.
12. Link JT and Sorensen BK (2000) A method for preparing C-glycosides related to phlorizin. Tetrahedron Lett 41:9212-9217.
13. +/glucose cotransporter (SGLT1) trafficking and function cause glucosegalactose malabsorption. Nat Genet 12:216-220.
14. Melander A (2004) Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes 53 (Suppl 3):S151-S155.
15. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, et al. (2004) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256-263.
16. +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794-1800.
17. +-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol 391:183-192.
18. +-glucose cotransporter (SGLT) inhibitors. Bioorg Med Chem Lett 13:2269-2272.
19. Pajor A and Wright EM (1992) Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family. J Biol Chem 267:3557-3560.
20. Proks P, Reimann F, Green N, Gribble F, and Ashcroft F (2002) Sulfonylurea stimulation of insulin secretion. Diabetes 51 (Suppl):S368-S376.
21. Rossetti L, Smith D, Shulman GI, Papachristou D, and DeFronzo RA (1987) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Investig 79:1510-1515.
22. Seidner G, Alvarez MG, Yeh JI, O'Driscoll KR, Klepper J, Stump TS, Wang D, Spinner NB, Birnbaum MJ, and De Vivo DC (1998) GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 18:188-191.
23. Silverman M and Turner RJ (1992) Glucose transport in the renal proximal tubule, in Handbook of Physiology. Section 8: Renal Physiology. Vol 2 (Windhager EE ed) pp 2017-2038, Oxford University Press, Oxford, UK.
24. +-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo) 44:1174-1180.
25. +-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem 42:5311-5324.
26. +/glucose cotransporter. Nature (Lond) 350:354-356.
27. +-glucose cotransporter suppresses blood glucose elevation in dogs. Biol Pharm Bull 29:114-118.
28. UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853.
29. van den Heuvel LP, Assink K, Willemsen M, and Monnens L (2002) Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 111:544-547.
30. Vichayanrat A, Ploybutr S, Tunlakit M, and Watanakejorn P (2002) Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 55:99-103.
31. Wheeler TJ and Hinkle PC (1981) Kinetic properties of the reconstituted glucose transporter from human erythrocytes. J Biol Chem 256:8907-8914.
32. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, and Hediger MA (1992) Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 263:F459-F465.
33. +-glucose cotransporters. Am J Physiol 280:F10-F18.
34. Zhang X, Urbanski M, Patel M, Zeck RE, Cox GG, Bian H, Conway BR, Pat Beavers M, Rybczynski PJ, and Demarest KT (2005) Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1. Bioorg Med Chem Lett 15:5202-5206.
35. Zhang X, Urbanski M, Patel M, Cox GG, Zeck RE, Bian H, Conway BR, Pat Beavers M, Rybczynski PJ, and Demarest KT (2006) Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2. Bioorg Med Chem Lett 16:1696-1701.